131468-33-2

Basic information

• Product Name: 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine
• Synonyms: 2,4-Dichloro-6-(4-fluorophenylamino)-1,3,5-triazine
• CAS NO: 131468-33-2
• Molecular Formula: C₉H₅Cl₂FN₄
• Molecular Weight: 259.07
• Mol File: 131468-33-2.mol
• Article Data: 22

Chemical Properties

• Boiling Point: 437.8°Cat760mmHg
• Flash Point: 218.6°C
• Appearance: /
• Density: 1.586g/cm³
• Vapor Pressure: 7.27E-08mmHg at 25°C
• Refractive Index: 1.651
• CAS DataBase Reference: 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine(131468-33-2)
• EPA Substance Registry System: 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine(131468-33-2)

Safety Data

• Hazardous Substances Data: 131468-33-2(Hazardous Substances Data)

Usage

General Description

4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is a chemical compound with the molecular formula C9H5Cl2FN4. It is a heterocyclic amine derivative that contains both chlorine and fluorine atoms. 4,6-Dichloro-N-(4-fluorophenyl)-1,3,5-triazin-2-amine is primarily used in the production of pharmaceuticals, agrochemicals, and dyes. It is also used as an intermediate in the synthesis of various organic compounds. The chemical's properties make it suitable for a wide range of applications, including as a building block in the synthesis of other complex molecules. It is essential to handle this chemical with care, as it may pose risks to human health and the environment if mishandled.

InChI:InChI=1/C9H5Cl2FN4/c10-7-14-8(11)16-9(15-7)13-6-3-1-5(12)2-4-6/h1-4H,(H,13,14,15,16)

Upstream product

• 108-77-0 1,3,5-trichloro-2,4,6-triazine 
• 371-40-4 4-fluoroaniline 

Downstream Products

• 539021-77-7 2-chloro-4-(4-fluoroanilino)-6-(4-methylanilino)-1,3,5-triazine 
• 131468-32-1 6-chloro-N²,N⁴-bis(4-fluorophenyl)-1,3,5-triazine-2,4-diamine 
• 924892-76-2 6-chloro-N-(4-fluorophenyl)-N'-(4-trifluoromethoxyphenyl)-1,3,5-triazine-2,4-diamine 
• 924892-75-1 6-chloro-N-(4-fluorophenyl)-N'-(4-methoxyphenyl)-1,3,5-triazine-2,4-diamine 
• 924892-68-2 N-benzyl-6-chloro-N'-(4-fluorophenyl)-1,3,5-triazine-2,4-diamine 
• 491866-89-8 C₁₄H₁₅ClFN₅ 

Relevant articles and documents

Synthesis and characterization of new s-triazine bearing benzimidazole and benzothiazole derivatives as anticancer agents

Two new series of s-triazine derivatives appended with benzimidazole (15a-h) and benzothiazole derivatives (16a-h) are synthesized, and structure-activity relationships on anticancer activity of these 15a-h and 16a-h were probed. In vitro inhibitory activity against the growth of six cancer cell lines, viz., MCF-7, MDAMB-231, PC-3, DU-145, HT-29 and HGC-27 was evaluated for synthesized analogues. Among the two series of compounds, derivatives containing benzimidazole scaffold were found to be relatively potent over benzothiazole analogues. In accordance with our previous observation, within benzimidazole derivatives, tri-substituted s-triazine derivatives were found to be more potent over di-substituted derivatives irrespective of cell lines. Structure-activity relationships provided useful insights into these classes of compounds and paved the way to design novel analogues with more potency.

Triazine-benzimidazole conjugates: Synthesis, spectroscopic and molecular modelling studies for interaction with calf thymus DNA

Triazine-benzimidazole analogues with different substitutions of primary and secondary amines as well as aryl groups were synthesized and characterized by 1H, 13C NMR and mass spectrometry. Interactions of these compounds with ct-DNA were explored by spectroscopic and viscometric techniques. These results and molecular modelling studies showed that compounds 7, 9-11, 16 and 21 interacted with ct-DNA through groove binding and not intercalation.

PIKFYVE INHIBITORS

The present application provides, inter alia, a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein Y, Ar, X1, X2, X3, R1, R2, R3, R4, R5, a

NOVEL CYCLIC GMP-AMP SYNTHASE (CGAS) INHIBITORS AND THEIR METHOD OF USE

Methods of treating diseases related to cGAS activation. Small molecule inhibitors of cGAS and pharmaceutical compositions and uses thereof in treating autoimmune diseases or inflammation.